PriceTargets.com logo

Urovant Sciences - UROV Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$16.24 As of 03/29/2021 01:00 AM ET
+0 (0.00%)
Get New Urovant Sciences Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for UROV and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for UROV

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Urovant Sciences in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $16.24.

This chart shows the closing price for UROV for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 contributing investment analysts is to n/a stock in Urovant Sciences. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/2/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/31/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/1/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/30/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/28/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/26/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/26/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/25/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/16/2020HC WainwrightReiterated RatingBuy ➝ Neutral$16.25Low
11/16/2020HC WainwrightDowngradeBuy ➝ Neutral$16.25Low
11/16/2020JPMorgan Chase & Co.Reiterated RatingOverweight ➝ Neutral$16.00Low
11/16/2020JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$16.00Low
11/13/2020Jefferies Financial GroupDowngradeBuy ➝ Hold$16.25High
6/19/2020HC WainwrightLower TargetBuy$33.00 ➝ $28.00High
6/10/2020HC WainwrightReiterated RatingBuyHigh
12/31/2019HC WainwrightBoost TargetBuy$28.00 ➝ $33.00High
10/21/2019HC WainwrightSet TargetBuy$28.00Low
9/9/2019HC WainwrightReiterated RatingBuy$28.00Medium
6/24/2019HC WainwrightSet TargetBuy$28.00Low
6/14/2019JPMorgan Chase & Co.Set TargetBuy$24.00Low
(Data available from 4/25/2019 forward)

News Sentiment Rating

0.00 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/28/2023
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/28/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/27/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/27/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/26/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/25/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/26/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/25/2024

Current Sentiment

  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
Urovant Sciences logo
Urovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for urologic conditions in the United States. The company's lead product candidate is vibegron, an oral small molecule beta-3 agonist for the treatment of overactive bladder (OAB), OAB in men with benign prostatic hyperplasia, and abdominal pain due to irritable bowel syndrome. It is also developing URO-902, a gene therapy for patients with OAB who have failed oral pharmacological therapy. The company was formerly known as Thalavant Sciences Ltd. and changed its name to Urovant Sciences Ltd. in January 2017. Urovant Sciences Ltd. was founded in 2016 and is based in London, the United Kingdom. Urovant Sciences Ltd. operates as a subsidiary of Sumitovant Biopharma Ltd.
Read More

Today's Range

Now: $16.24
Low: $16.24
High: $16.24

50 Day Range

MA: $16.23
Low: $16.19
High: $16.24

52 Week Range

Now: $16.24
Low: $7.15
High: $16.26

Volume

N/A

Average Volume

114,469 shs

Market Capitalization

$531.75 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.36

Frequently Asked Questions

What sell-side analysts currently cover shares of Urovant Sciences?

The following sell-side analysts have issued stock ratings on Urovant Sciences in the last twelve months:
View the latest analyst ratings for UROV.

What is the current price target for Urovant Sciences?

0 Wall Street analysts have set twelve-month price targets for Urovant Sciences in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Urovant Sciences in the next year.
View the latest price targets for UROV.

What is the current consensus analyst rating for Urovant Sciences?

Urovant Sciences currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for UROV.

What other companies compete with Urovant Sciences?

Other companies that are similar to Urovant Sciences include Phathom Pharmaceuticals, Astria Therapeutics, ArriVent BioPharma, Altimmune and Stoke Therapeutics. Learn More about companies similar to Urovant Sciences.

How do I contact Urovant Sciences' investor relations team?

Urovant Sciences' physical mailing address is 11-12 STREET JAMES SQUARE SUITE 1 3RD FLOOR, LONDON X0, SW1Y 4LB. The company's listed phone number is 44-0-20-7400-3347 and its investor relations email address is [email protected]. The official website for Urovant Sciences is www.urovant.com. Learn More about contacing Urovant Sciences investor relations.